Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients

Hamaya, Tomoko; Yoneyama, T.; Tobisawa, Yuki; Kodama, Hirotake; Fujita, Takeshi; Murakami, Reiichi; Fujita, Naoki; Okamoto, Teppei; Yamamoto, Hayato; Yoneyama, Takahiro; Hashimoto, Yasuhiro; Saitoh, Hisao; Narumi, Shunji; Tomita, Hirofumi; Οhyama, Chikara

doi:10.1038/s41598-022-09897-0

Cited by 13 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Murhekar and colleagues [37] reported seroprevalence rates of 81% and 89.8% among adults who had received one dose and 2 doses of COVID-19 vaccines respectively. Similarly, Hamaya et al [43] reported seroprevalence rate of 98% among healthy adults after the second dose of the BNT162b2 mRNA vaccine. Our study is in tandem with these previous studies as 69.2% and 73.8% seroprevalence rates were observed post first and second doses of COVID-19 vaccine respectively.…”

Section: Plos Onementioning

confidence: 86%

See 1 more Smart Citation

Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians

et al. 2023

View full text Add to dashboard Cite

Background Reports on the evaluation of immune responses to different COVID-19 vaccines are limited. Similarly, effects of age and gender have not been well explored as variables that could impact on the vaccine-induced antibody response. Therefore, seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians was determined in this study. Methodology A total of 141 adults were enrolled into this study. Presence or absence of SARS-CoV-2 infection was confirmed by real-time reverse-transcriptase polymerase-chain reaction (RT-PCR) assay on nasopharyngeal and oropharyngeal swab specimens. Anti-SARS-CoV-2 Specific IgG and IgM antibodies were qualitatively detected using a Rapid Diagnostic Test kit. Results Pre-vaccination, 77% of the study participants had never had PCR-confirmed COVID-19 test yet 66.7% of them were seropositive for SARS-CoV-2 antibodies. Of 111 COVID-19 vaccinated participants, 69.2% and 73.8% of them had SARS-CoV-2 specific IgG post-first and second doses of COVID-19 vaccine respectively. However, 23.1% and 21.4% of the participants who have had first and second doses respectively had no detectable anti-SARS-CoV-2 antibodies. The proportion of participants with SARS-CoV-2 specific IgG was insignificantly higher in those between the ages of 18–40 years and 41–59 years compared with individuals aged ≥60 years. No significant association was observed between gender and seropositivity for SARS-CoV-2 antibodies. Conclusion There is high SARS-CoV-2 antibody seroprevalence among Nigerian adults who never had PCR-confirmed COVID-19. Also, there is the need for anti-SARS-CoV-2 antibodies screening post vaccination as this could be essential in achieving herd immunity. Age and gender do not seem to have significant association with seropositivity.

show abstract

Section: Plos Onementioning

confidence: 86%

“…Similarly, Hamaya et al . [ 43 ] reported seroprevalence rate of 98% among healthy adults after the second dose of the BNT162b2 mRNA vaccine. Our study is in tandem with these previous studies as 69.2% and 73.8% seroprevalence rates were observed post first and second doses of COVID-19 vaccine respectively.…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians

et al. 2023

View full text Add to dashboard Cite

show abstract

“…They reported antibody titers were not significantly deteriorated in patients with steroid treatment for immune-related adverse events. Moreover, organ transplant recipients receiving multidrug immunosuppressive therapy are known to have significantly suppressed immune responses to mRNA vaccines [ 13 , 19 ]. It is reported that not the dose alone but the cumulative dose is considered important for estimating the risk of infection from steroids (the risk associated with 5mg prednisolone taken for the last 3 years was similar to that associated with 30 mg taken for a month) [20] .…”

Section: Discussionmentioning

confidence: 99%

“…Blood samples for regular examination were cross-sectionally obtained. The titers of the immunoglobulin G (IgG) antibodies against the SARS-CoV-2 spike (S) receptor-binding domain were determined using the Elecsys anti-SARS-CoV-2 S RUO (Covas 8000/e 801; Roche-Diagnostics, Mélan, France) as described previously [ 13 , 14 ]. We used IgG titers of 15 U/mL or more, which is sufficient for the presence of neutralizing antibodies, as a cutoff value in this study.…”

Section: Methodsmentioning

confidence: 99%

Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids

Yoneyama

Tanaka

Narita

et al. 2022

Urologic Oncology: Seminars and Original Investigations

Self Cite

View full text Add to dashboard Cite

“…To avoid multi-collinearity, only variables with VIF<10 were included in multivariate analysis. A multivariate logistic regression model was built to analyze risk factors of BTI, adjusting for age, kidney graft function and mycophenolate mofetil use, considered as important variables influencing immune responses to SARS-CoV-2 vaccination, based on our linear regression data and on published data (30, 31) . Missing data were excluded from the final analysis.…”

Section: Methodsmentioning

confidence: 99%

Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients

Kemlin

Gemander

Depickère

et al. 2022

Preprint

View full text Add to dashboard Cite

As solid organ recipients are at high risk of severe COVID-19 and respond poorly to primary SARS-CoV-2 mRNA vaccination, they have been prioritized for booster vaccination. However, an immunological correlate of protection has not been identified in this vulnerable population. We conducted a prospective monocentric cohort study of 65 kidney transplant recipients who received three doses of SARS-CoV-2 BNT162b2 mRNA vaccination. Associations between symptomatic breakthrough infection (BTI) and vaccine responses, patient demographic and clinical characteristics were explored. Symptomatic COVID-19 was diagnosed in 32% of kidney transplant recipients during a period of six months after the administration of the third vaccine dose. During this period, SARS-CoV-2 delta and omicron were the dominant variants in the general population. Univariate analyzes identified avidity of SARS-CoV-2 receptor binding domain (RBD) binding IgG, neutralizing antibodies and SARS-CoV-2 S2 domain-specific IFN-gamma responses as correlates of protection against BTI. Some demographic and clinical parameters correlated with vaccine responses, but none correlated with the risk of BTI. In multivariate analysis, the risk of BTI was best predicted by neutralizing antibody and S2-specific IFN-gamma responses, adjusting for age, graft function and mycophenolate mofetil use. In conclusion, both antibody and T cell responses predict the risk of BTI in kidney transplant recipients who received three doses of SARS-CoV-2 mRNA vaccine. T cell responses may help compensate for the suboptimal antibody response to vaccination in this vulnerable population.

show abstract

Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients

Cited by 13 publications

References 25 publications

Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians

Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians

Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids

Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients

Contact Info

Product

Resources

About